Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Skyworks Solutions Inc (SWKS) vs 10X Genomics Inc (TXG) Price & Performance

Skyworks Solutions IncTrade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

Skyworks Solutions Inc vs 10X Genomics Inc — how do they compare? Skyworks Solutions Inc trades at $76.14 (market cap $11.34B), while 10X Genomics Inc trades at $67.8 (market cap $8.55B). The key difference: Skyworks Solutions Inc is the larger of the two by market cap, and Skyworks Solutions Inc pays a 4.13% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.

SWKSTXG
Market Cap
$11.34B$8.55B
Sector
TechnologyHealth
52-Week High
$83.40$67.29
52-Week Low
$52.50$11.34
Enterprise Value
$11.22B$8.08B
Dividend Yield
4.13%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Skyworks Solutions Inc

Skyworks Solutions (SWKS) trades at $75.38, up 1.84% with bullish technical signals from moving averages. The stock shows strong earnings momentum with three consecutive quarterly beats, though revenue has declined from $5.5B in 2022 to $4.1B in 2025. Analyst consensus is positive with 58% buy ratings, though the current price exceeds the $66.44 consensus target. Recent institutional buying and conference participation indicate ongoing investor interest despite margin compression and revenue headwinds.

The outlook remains cautiously optimistic with AI data center growth providing upside potential, but investors face risks from declining profitability margins and ongoing revenue contraction. The stock's elevated P/E ratio of 39.06 requires continued earnings growth justification, while technical indicators show potential resistance near $76-77 levels.

10X Genomics Inc

TXG trades at $65.60, up 4.71% today, with strong technical momentum showing bullish moving averages and key support at $63. Fundamentally, the company demonstrates improving trends with Q2 2026 earnings beating estimates and revenue growth guidance raised, though profitability remains negative with a -12.18% net margin. Recent patent victory against Parse Biosciences strengthens competitive positioning.

The outlook remains cautiously optimistic with analyst consensus at 45% buy ratings and $50.78 price target. Key opportunities include Atera platform adoption and consumables growth, while risks center on valuation premiums and ongoing profitability challenges. The stock trades near resistance at $67 with institutional interest showing mixed signals.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Skyworks Solutions Inc

Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.

Read more on SWKS

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG